The utility of imatinib in either the pre-or post-transplant period for Ph chromosome-positive (Ph þ ) ALL is uncertain. In addition, there have been recent concerns regarding imatinib and cardiac toxicity. We investigated the outcome of 32 patients with Ph þ ALL who received an allo-hematopoietic cell transplant (HCT) at the University of Minnesota between 1999 and 2006. The median age at HCT was 21.9 years (range: 2.8-55.2). All patients were conditioned with CY and TBI. GVHD prophylaxis was CsA based. Of the 32 patients, 15 received imatinib therapy pre-or post-HCT (imatinib group) and 17 patients received either no imatinib (n ¼ 11) or only after relapse (n ¼ 6) (non-imatinib group). Overall survival, relapse-free survival and relapse at 2 years was 61, 67 and 13% for the imatinib group as compared with 41, 35 and 35% for the non-imatinib group (P ¼ 0.19, 0.12 and 0.20, respectively). Cardiac toxicity and TRM at 2 years were similar between groups. Thus, patients treated with imatinib in either the pre-or post-transplant setting had trends toward improved outcomes and no increase in cardiac toxicity. We suggest that imatinib be included in the peri-transplant management of all patients with Ph þ ALL.
Introduction
Approximately 3-5% of children and 20-25% of adults diagnosed with ALL will have a malignant clone expressing the Ph chromosome. 1, 2 These patients often present with an aggressive leukemia that is resistant to standard therapy and results in high rates of relapse. Disease-free survival (DFS) using standard chemotherapy is reported to be 25-30% in children and less than 20% for adults. 3 Earlier studies have shown that allo-hematopoietic cell transplant (HCT) from a matched-related donor decreases relapse rates, resulting in improved DFS to 40-60%. [4] [5] [6] [7] At the gene level, the Ph þ chromosome is created by a translocation of the 5 0 portion of the bcr gene to the kinase domain of the abl gene, resulting in a novel fusion protein with unregulated tyrosine kinase (TK) activity. In 1999, imatinib was approved for human use as a competitive inhibitor directed toward this abl TK fusion gene found in both CML and Ph þ ALL. Since its introduction, imatinib has markedly replaced the need for allo-HCT in adults with CML. Imatinib has recently been used in adult patients with Ph þ ALL in conjunction with standard chemotherapy and allo-HCT with mixed results reported. [8] [9] [10] [11] Thus, the utility of imatinib in either the pre-or post-transplant period for Ph þ ALL remains uncertain. In addition, there have been concerns regarding imatinib and cardiac toxicity, notably congestive heart failure (CHF), in both preclinical studies and some clinical series. [12] [13] [14] [15] Owing to the concern of imatinib-related cardiac failure and the potential risk of further cardiac toxicity through pre-HCT conditioning, we investigated our transplant outcomes and cardiac toxicities for patients with Ph þ ALL who received a myeloablative allo-HCT since the time imatinib became commercially available.
Patients and methods
A total of 32 patients with Ph þ ALL received a myeloablative allo-HCT at the University of Minnesota between 1999 and 2006. The diagnosis of Ph þ ALL was based on the presence of the (9;22) translocation on standard karyotype analysis, FISH and/or the bcr-abl fusion transcript detected by PCR. Two patients did not have the (9;22) translocation but had chromosomal changes involving chromosome 9, resulting in abl gene amplification by FISH, and were included in this analysis. All patients and/or guardians underwent informed consent prior to transplant on Institutional Review Board-approved treatment protocols. As well, this retrospective analysis of patients was approved by the University of Minnesota institutional review board.
The median age at HCT was 21.9 years (range: 2.8-55.2). Eighteen (56.3%) patients were male. Prior to HCT, 20 patients were in first CR (CR1) and 12 patients were in CR2. Donor source was HLA partially matched unrelated umbilical cord blood (UCB) (n ¼ 17), HLA-matched sibling BM or PBSC (n ¼ 12) and HLA-matched unrelated BM (n ¼ 3). All patients were conditioned with CY (120 mg/kg) and TBI (range: 1320-1375 cGy) with CsA-based GVHD prophylaxis. Neutrophil engraftment was defined as 2 consecutive days with an ANC of 4500/ml, and platelet recovery was defined as an unsupported platelet count of 420 000/ml for 3 consecutive days and 7 prior platelet transfusion-free days.
Patients were assigned to low-, intermediate-and highrisk groups based on their presenting age and WBC. 3, 16 Of the 32 patients, 6 were considered high-risk (WBC4100 k, any age), 8 low-risk (WBCo50 k, ageo10 years) and the remaining 18 patients were intermediate-risk (WBCo100 k, any age). Fifteen patients received imatinib therapy either pre-or post-HCT (9 pre-HCT, 2 pre/ post-HCT, 2 post-HCT and 2 pre-HCT and at relapse) comprising the imatinib group, whereas the remaining 17 patients either never received imatinib (n ¼ 11) or received it only at the time of relapse post-HCT (n ¼ 6) were the nonimatinib group (Table 1) . The decision whether to initiate imatinib therapy prior to allo-HCT was made by the referring physician and was not typically the standard of practice. Post-allo-HCT imatinib therapy was decided by the transplant physician at the University of Minnesota, which also varied by physician, as no standard practice existed at the time. The majority of patients in the nonimatinib group received their HCT prior to 2004 when imatinib therapy was less likely to be considered standard practice. Imatinib doses ranged from 240 to 340 mg/m 2 /day for the pediatric patients and 400 to 800 mg/day for adults. When imatinib therapy was initiated post-allo-HCT, it began on average, at day þ 120 (range: 80-180) and continued through day þ 365.
Pre-transplant cardiac function was determined in all patients using both electrocardiogram (EKG) and echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans. Therapy-related cardiac toxicity was defined as a left ventricular ejection fraction o40%, cardiac hypertrophy, EKG abnormalities (ST changes, Twave abnormalities and/or ischemia) or pericardial effusions that developed between the time of transplant and 1-year post-HCT. Of the 32 patients, 31 (96.9%) received prior anthracycline therapy with the 1 patient exception due to a history of a previous myocardial infarction.
Statistical methods
Four outcome variables were studied: overall survival (OS), relapse-free survival (RFS), risk of relapse and post-HCT cardiac toxicity comparing the two imatinib groups. The Kaplan-Meier method was used to estimate OS and RFS, whereas cumulative incidence was estimated for the risk of relapse and cardiac toxicity. The log-rank test was used for comparing survival curves and the Gray test for cumulative incidence curves between the two imatinib use groups. Multiple regression analysis was conducted for OS, RFS and risk of relapse. Specifically, Cox's proportional hazards model was used for OS and RFS, and Fine-Gray model for risk of relapse. Imatinib use was the primary factor being considered for each end point. The other covariates adjusted in the models included CR status, disease risk group, conditioning regimen, stem cell source, single vs double UCB, HLA type, GVHD, GVHD prophylaxis and age.
Results
There was no significant difference between the imatinib and non-imatinib group with regard to median time to transplant from diagnosis (164 vs 154 days, respectively, P ¼ 0.91) neutrophil engraftment (23 vs 24 days, respectively, P ¼ 0.65) or platelet recovery (57 vs 47 days, respectively, P ¼ 0.87).
The cumulative incidence of grades 2-4 and 3-4 acute GVHD was lower in the imatinib group (27 and 0%) as compared with the non-imatinib group (35 and 18%), but the difference was not statistically significant (P ¼ 0.62, P ¼ 0.09, respectively). The cumulative incidence of chronic GVHD for the non-imatinib (18%) and imatinib groups (20%) were similar (P ¼ 0.97) at 1 year after transplantation.
There was a statistically significant difference identified between imatinib groups regarding conditioning regimen, GVHD prophylaxis and stem cell source reflecting our institutional treatment and protocol changes over the years. The imatinib group patients were more likely to receive fludarabine during transplant conditioning and GVHD prophylaxis with CsA/mycophenolate mofetil (MMF) (67%) as compared with the non-imatinib group patients (18%) (P ¼ 0.02 and P ¼ 0.01, respectively). UCB stem cells were used more frequently in the imatinib group patients (80%) as compared with the non-imatinib group (29%) who received more PBSC/BM grafts (71%) (P ¼ 0.01) ( Table 1) .
Among the 32 patients, 3 died of transplant-related causes in the imatinib group and 5 in the non-imatinib group, giving similar TRMs at 2 years (20 and 29%, respectively; P ¼ 0.57). The causes of TRM for the imatinib group included infection (n ¼ 2) and multi-organ failure (n ¼ 1) as compared with infection (n ¼ 1), GVHD (n ¼ 1) and multi-organ failure (n ¼ 3) for the non-imatinib group.
The median follow-up time is 0.93 years (range: 0.04-4.86). Of the 32 patients, 8 have relapsed (2 imatinib and 6 non-imatinib) a median of 101 days after HCT (range: 68-293), providing an incidence of relapse of 13 and 35% for the imatinib and non-imatinib groups, respectively (P ¼ 0.20) (Figure 1 ). OS and RFS at 2 years was 61 and 67% for the imatinib group as compared with 41 and 35% for the non-imatinib group (P ¼ 0.19 and 0.12, respectively) (Figures 2 and 3) .
In comparing the 15 patients who received imatinib therapy either pre-HCT (n ¼ 13) or post-HCT (n ¼ 2), outcomes were reported with regard to OS, RFS and risk of relapse. There were two relapses in the pre-HCT imatinib group (days þ 68 and þ 118) as compared with no relapses reported in the post-HCT imatinib group (n ¼ 2) at 2 years (P ¼ 0.55). The two pre-HCT imatinib group patients who relapsed received imatinib therapy for 1 month prior to HCT and did not receive it as a maintenance therapy after HCT. OS and RFS at 2 years were 7 of 13 (52%) and 9 of 13 (62%) for the pre-HCT imatinib group as compared with 2 of 2 (100%) and 2 of 2 (100%) for the post-HCT imatinib group (P ¼ 0.28 and 0.34, respectively). Of the 12 patients who received post-HCT imatinib (6 non-imatinib group and 6 imatinib group) either at the time of relapse or as a maintenance therapy, only 1 patient (non-imatinib group) had imatinib therapy interrupted because of anemia/neutropenia and subsequently reported a second relapse shortly after imatinib was stopped. The remaining 11 patients tolerated imatinib well without drug interruption. a Among these 15 people, 2 had both pre-and post-HCT imatinib, and 2 had both pre-HCT imatinib and post-relapse. b The P-value for CR status between the imatinib (CR1 ¼ 60.0%, CR2 ¼ 40.0%) and the non-imatinib groups (CR1 ¼ 64.7%, CR2 ¼ 35.3%) is 0.78. c One patient with t(9;10) and amplified abl in CR2; one patient with T-cell ALL and amplified abl in CR2.
Multiple regression analysis was conducted for OS, RFS and risk of relapse with imatinib use included in all models. The hazard ratios (HRs) for the imatinib group as compared with the non-imatinib group for OS and RFS were 0.92 (95% CI: 0.18, 4.56) (P ¼ 0.92) and 0.58 (95% CI: 0.12, 2.90) (P ¼ 0.51), respectively. The HR for relapse between the two groups was 0.12 (95% CI: 0.02, 0.85) in favor of imatinib use (P ¼ 0.03). OS had a trend toward being significantly decreased in patients with grade III-IV GVHD (HR ¼ 6.04, P ¼ 0.07) as did RFS for patients who received PBSC (against BM, HR ¼ 4.92, P ¼ 0.07). PBSC recipients also had a trend toward greater relapse as compared with BM recipients (HR ¼ 11.74, P ¼ 0.1). Risk of relapse was increased in CR2 patients (HR ¼ 11.62, P ¼ 0.03) as compared with CR1, but decreased in the Ph þ low-risk group (against intermediate risk, HR ¼ 0.15, P ¼ 0.04). The effect of GVHD on relapse could not be estimated because of the presence of competing death events. The significant difference identified in the transplant conditioning regimen, GVHD prophylaxis or UCB graft source between the two imatinib groups was not found to impact on transplant outcome in this multiple regression analysis.
Cardiac function was evaluated in all 32 patients prior to HCT and again at 1 year after HCT. Patient charts were reviewed for additional cardiac evaluations or cardiology consultations. Of the 32 patients, a total of 10 (3 imatinib and 7 non-imatinib) patients in this analysis had reported cardiac toxicity, ranging from grades 2 to 4 according to the National Cancer Institute Common Toxicity Criteria (NCI CTC version 3.0). Of these 10 patients, 5 had symptomatic toxicities (Grade 3-4). Of the 15 imatinib group patients, 3 (22%) had evidence of grade 3-4 cardiac toxicity as compared with 2 of 17 (12%) non-imatinib group patients (P ¼ 0.47) at 1 year after HCT ( Table 2 ). The three imatinib group patients reporting grade 3-4 cardiac toxicity received imatinib (400 mg daily) in the pre-HCT setting for 30, 90 and 100 days each (UPN (unique patient number) 4354: 30 days; UPN 4175: 90 days; UPN 4479: 100 days) with cardiac events occurring on days þ 78, þ 345 and þ 84 after HCT, respectively.
Discussion
Despite increasing treatment intensity, Ph þ ALL continues to carry a poor prognosis for both children and adults due to higher rates of relapse. [17] [18] [19] Since the FDA approval of imatinib and its use in Ph þ ALL with multiagent chemotherapy, outcomes have varied. [8] [9] [10] [11] de Labarthe et al. 9 recently reported their experience with 22 Ph þ ALL adult patients treated with imatinib and chemotherapy prior to an allo-HCT, with OS rates of 65% at 18 months. Similar results were reported by Yanada et al., 10 where 80 adult patients with Ph þ ALL received imatinib during induction/consolidation therapy. CRs were observed in 77 of 80 (96.2%) patients and 1-year OS rates of 73.3% in patients receiving allo-HCT as compared with 84.8% in patients treated with chemotherapy alone. Although the increased survival reported by De Labarthe and Yanada are encouraging, the follow-up time is relatively short as late relapses continue to be a problem despite pre-HCT imatinib. 8, 11 Not all reports of imatinib use in the treatment of Ph þ ALL have been positive. Fielding et al.
11 presented the Imatinib group (n = 15) Figure 1 Cumulative incidence of relapse. The cumulative incidence of relapse for these two groups (imatinib group vs non-imatinib group) at 1 year was 13 and 35%, respectively (P ¼ 0.20). Relapse-free survival Figure 3 Relapse-free survival (RFS). RFS at 2 years was 67% for the imatinib group as compared with 35% for the non-imatinib group.
UKALLXII/ECOG2993 Study results in abstract form in 2007, where they analyzed 153 Ph þ ALL patients treated with imatinib, 57 (58%) of which proceeded to allo-HCT. In this analysis, they found no survival advantage for the imatinib group at 3 years, when compared with 267 nonimatinib-treated patients with Ph þ ALL (23 vs 26%, respectively).
Our retrospective analysis, although involving a heterogeneous group of Ph þ ALL patients, shows that imatinib use either pre-or post-allo-HCT does not negatively impact on OS/RFS or increase TRM, confirming the results of others. 12, 20, 21 Although we are reporting a limited number of patients, imatinib administration given either pre-or post-HCT was associated with a significant decrease in relapse in multiple regression analysis. One should take care interpreting results regarding the impact that post-HCT imatinib maintenance alone may have on relapse, as we are reporting just two imatinib group patients who received imatinib only in the post-HCT setting as maintenance.
Although not reaching statistical significance, it is unclear as to why patients who received PBSC as compared with BM trended toward higher rates of relapse and lower RFS in our analysis. In a retrospective study by Champlin et al. 22 through the International Bone Marrow Transplant Registry (IBMTR)/European Bone Marrow Transplant Registry (EBMTR) of 112 adult ALL patients (38 PBSC vs 74 BM), there was no difference in relapse between graft sources, but improved leukemia-free survival (LFS) was shown in CR2 patients receiving PBSC (P ¼ 0.03). This report is contrasted by the Garderet et al. 23 analysis through the Acute Leukemia Working Body of the EBMTR, which reported a trend toward greater relapse in 102 ALL patients receiving PBSC (n ¼ 36) than BM (n ¼ 66) (47 vs 39%, P ¼ 0.17) and lower LFS/OS in the PBSC group (P ¼ 0.04). Although there was no significant difference in relapse in either of these analyses between PBSC and BM, and contrasting results regarding LFS, it remains unclear whether PBSC alter the relapse risk or LFS, when compared with BM in ALL.
Although imatinib usage is now more routinely incorporated into chemotherapy regimens for adults with Ph þ ALL, there is still much to learn regarding the function of TK inhibitors in children. The impact that imatinib or other TK inhibitors (that is, dasatinib and nilotinib) may have on children with Ph þ ALL who undergo allo-HCT has yet to be determined, and their effect on the risk of relapse and RFS is unknown. The Children's Oncology Group (COG) recently completed a study using imatinib in Ph þ ALL patients throughout their treatment course. In patients who had an MSD and underwent allo-HCT, imatinib was continued for 6 months after HCT. The results of this study were presented in abstract form in 2007, reporting significantly improved 1-year EFS in patients treated with imatinib as compared with historical controls for both the chemotherapy alone and HCT arms. 24 Whether or not the addition of imatinib during the pre-and post-HCT period for this COG cohort will prevent further relapse is presently unclear but will be answered in due course as the study matures.
We observed that imatinib-treated patients had a decreased risk of relapse as compared with the nonimatinib patients. Recently, a number of leukemia studies, in both children and adults, have shown that lower levels of minimal residual disease (MRD) prior to HCT are associated with improved outcomes, when compared with patients with higher MRD levels. [25] [26] [27] One possible explanation for our findings is that pre-HCT imatinib results in more effective leukemia cell kill and less MRD present prior to transplant. Similarly, post-HCT imatinib could theoretically delay the kinetics of leukemia regrowth, while any GVL effect was occurring. As the majority of patients in this analysis were initially treated elsewhere prior to referral for allo-HCT, MRD analysis pre-HCT was either not performed or unavailable at the time of this analysis.
Another reason for the potentially less relapse seen in the imatinib group could be the greater HLA disparity among the graft sources as more imatinib group patients received UCB grafts (n ¼ 12) as compared with the non-imatinib group (n ¼ 5). With this greater chance for HLA disparity in UCB grafts as compared with BM or PBSC, the imatinib-treated patients may have had a greater GVL potential, when compared with the non-imatinib patients who received more BM and PBSC as a graft source, all of which were well matched (HLA typing 6/6). Whether or not the greater degree of HLA disparity seen in the UCB grafts provided a stronger potential for GVL to occur is unclear and could not be determined in our small cohort. However, we have recently shown that the rate of relapse after UCB transplants is similar to BM and therefore no advantage regarding relapse or a greater potential for GVL may exist between these graft sources. 28 The concern that imatinib may lead to cardiac-related toxicities, notably CHF, has been previously described 13, 14, 29 and was reported again recently by Kerkela et al. 15 These investigators described 10 patients who presented with severe CHF without any other obvious cause while receiving imatinib. Through a series of very elegant in vitro and in vivo studies, the authors implicated cardiac toxicity as an unanticipated side effect of the c-abl inhibition by imatinib. Although these patients were reported to have no obvious cause for their CHF, seven of these patients had a prior history of hypertension, four with diabetes and three with coronary artery disease.
Since this original study, there have been no further reports to support cardiac-associated risks of imatinib in either adults or children. Atallah et al. recently reported over 1200 CML patients treated with imatinib. CHF was present in 22 of 1276 (1.7%) patients, with 18 of these 22 patients (82%) having a previously diagnosed cardiovascular illness. 30 The authors concluded that although the potential of cardiac-related toxicity does exist while on imatinib, it is a rare event and mainly seen in elderly patients with a preexisting cardiac condition.
We evaluated the frequency of cardiac toxicity in our patients who had undergone a myeloablative allo-HCT and received imatinib either pre-or post-HCT. The expected risk of a serious cardiac-related event (NCI CTC grade [4] [5] in the first 100 days after allo-HCT has been previously estimated at our institution to be o1%. 31 What impact imatinib therapy may have on the cardiac risk for patients undergoing a myeloablative allo-HCT has not been extensively studied. There was a brief report by Sohn et al. 13 who identified two accelerated phase CML patients treated with imatinib therapy prior to a myeloablative allo-HCT who later developed CHF at days þ 5 and þ 27 after HCT. These two patients, conditioned with BU and CY, were compared with 45 non-imatinib-treated leukemia patients who received identical conditioning for an allo-HCT and did not develop cardiac failure. The authors concluded that myeloablative allo-HCT for advanced-stage CML may increase the risk for cardiac failure in patients with prior imatinib therapy.
Symptomatic cardiac toxicities (grade 3-4) were reported in 5 of our 32 patients (3 imatinib group and 2 non-imatinib group patients), suggesting no increase in cardiac risk when imatinib was used during the peri-transplant period. The three imatinib patients reporting grade 3-4 cardiac toxicity all received imatinib prior to their CY/TBI conditioning as pre-HCT therapy and did not receive it as post-HCT maintenance therapy. Two of the three imatinib group patients had toxicity reported within the first 100 days post-HCT (pericardial effusion (n ¼ 1) and ischemia/T-wave abnormality (n ¼ 1)) with the third patient reporting a late toxicity closer to 1-year post-HCT (cardiac hypertrophy and T-wave abnormality). To determine whether imatinib truly does not confer cardiac risk in patients receiving a myeloablative allo-HCT, a much larger sample size would be necessary along with longer follow-up to identify the potential for late cardiac toxicities.
In conclusion, on the basis of this retrospective analysis of a heterogeneous group of Ph þ ALL patients, imatinib use in the peri-transplant period had no impact on either TRM or cardiac toxicity and resulted in a decreased rate of relapse. It remains unclear what impact imatinib may have when used as maintenance therapy in the post-HCT setting in this disease group, as we report only two patients who received post-HCT imatinib as maintenance therapy only, although both of whom have shown no relapse and remain in CR. Therefore, the decision to use imatinib, or perhaps other TK inhibitors, in Ph þ ALL patients at the time of diagnosis should be encouraged as it may positively impact on transplant outcome.
